Schedule of Financial Information Operating Segment (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Dec. 31, 2025 |
Sep. 30, 2025 |
Dec. 31, 2024 |
Sep. 30, 2024 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Segment Reporting Information [Line Items] | ||||||
| Consultants and other research and development | $ 1,164,737 | $ 1,220,535 | $ 1,974,728 | $ 2,535,394 | ||
| Stock-based compensation expense | 198,530 | 564,333 | 436,174 | 851,253 | ||
| Interest expense | 17,439 | 59,696 | 34,878 | 119,393 | ||
| Interest income | (85,410) | (7,067) | (195,026) | (33,073) | ||
| Grant income | 552,576 | 177,703 | 562,401 | 423,065 | ||
| Other | (34) | 47 | (130) | (236) | ||
| Net loss | (1,999,397) | $ (2,158,354) | (2,463,030) | $ (2,200,736) | (4,157,751) | (4,663,766) |
| Operating Segments [Member] | ||||||
| Segment Reporting Information [Line Items] | ||||||
| Pre-clinical and clinical studies | 928,288 | 455,039 | 1,335,200 | 1,288,900 | ||
| Contract manufacturing | 47,835 | 435,999 | 168,420 | 651,465 | ||
| Consultants and other research and development | 188,614 | 329,497 | 471,108 | 595,029 | ||
| Compensation and related benefits | 632,123 | 423,899 | 953,459 | 730,512 | ||
| Professional and consultant fees | 478,283 | 196,282 | 1,188,477 | 512,076 | ||
| Directors’ and officers’ insurance | 113,518 | 122,983 | 223,847 | 240,141 | ||
| Facilities, fees and other related costs | 32,719 | 60,119 | 103,485 | 130,899 | ||
| Interest expense | 17,439 | 59,696 | 34,878 | 119,393 | ||
| Interest income | (85,410) | (7,067) | (195,026) | (33,073) | ||
| Grant income | (552,576) | (177,703) | (562,401) | (423,065) | ||
| Other | 34 | (47) | 130 | 236 | ||
| Net loss | $ (1,999,397) | $ (2,463,030) | $ (4,157,751) | $ (4,663,766) | ||
| X | ||||||||||
- Definition Facilities fees and other related costs. No definition available.
|
| X | ||||||||||
- Definition Grant income. No definition available.
|
| X | ||||||||||
- Definition Preclinical and clinical studies. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate costs incurred in the production of goods for sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Insurance and claims costs directly related to goods produced and sold, or services rendered, during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|